DDInter1467 DDInter927
Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors. Unlike other atypical antipsychotics, pimavanserin lacks inherent dopaminergic activity. In fact, pimavanserin is the first antipsychotic drug without D<sub>2</sub> blocking activity. Therefore, pimavanserin can be used to treat psychotic symptoms without causing extrapyramidal or worsening motor symptoms.[A232613,A232573] Pimavanserin is marketed under the trade name NUPLAZID and developed by Acadia Pharmaceuticals. It was approved by the FDA in April 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Pimavanserin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Pimavanserin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zafirlukast
Pimavanserin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bosutinib
Pimavanserin {u} may lead to a major life threatening interaction when taken with {v} Toremifene
Pimavanserin {u} may lead to a major life threatening interaction when taken with {v} Vemurafenib
Pimavanserin may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast
Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Pimavanserin may lead to a major life threatening interaction when taken with Toremifene
Pimavanserin may lead to a major life threatening interaction when taken with Vemurafenib